Ioflupane (123i) Rotop

Ioflupane, the active ingredient in Ioflupane (123i) Rotop, is a radiopharmaceutical presented as a solution for injection for intravenous use. It binds to presynaptic dopamine transporters to enable imaging of dopaminergic neuron integrity, aiding differential diagnosis of Parkinsonian syndromes and assessment of movement disorders.

GNH USA supplies Ioflupane (123i) Rotop as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Ioflupane (123i) Rotop is used in nuclear medicine to image dopamine transporters in disorders of the basal ganglia. - Parkinsonian syndromes: assists in differential diagnosis by visualizing dopaminergic neuron loss. - Essential tremor: helps distinguish tremor etiology through dopamine transporter imaging. - Other movement disorders: provides assessment of dopaminergic system integrity for clinical evaluation.

Adverse reactions to Ioflupane (123i) Rotop are generally related to the radiopharmaceutical nature of the product and the injection procedure.

Common Side Effects: - Injection site pain: mild discomfort at the venipuncture site. - Nausea: transient feeling of queasiness following administration. - Headache: mild to moderate headache reported in some patients. - Flushing: temporary reddening of skin, especially face or neck.

Serious or Rare Side Effects: - Allergic reaction: urticaria, rash, or anaphylaxis requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure post‑injection. - Radiation‑related toxicity: unlikely but possible exposure‑related effects in high cumulative doses.

When using Ioflupane (123i) Rotop, clinicians should observe several safety and handling precautions. - Patient selection: confirm indication for dopamine transporter imaging before administration. - Pregnancy: avoid use unless benefits outweigh potential fetal radiation exposure. - Breastfeeding: discontinue breastfeeding for an appropriate period after injection due to possible tracer excretion. - Renal function: assess kidney function as impaired clearance may affect tracer distribution. - Concomitant medications: review drugs that may interfere with dopamine transporter binding, such as certain antidepressants or stimulants. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Ioflupane (123i) Rotop may interact with substances that affect dopamine transporter availability or alter radiopharmaceutical distribution.

Major Interactions (Avoid): - Cocaine or amphetamines: these drugs occupy dopamine transporters and can markedly reduce tracer binding, compromising image quality. - Certain antidepressants (e.g., bupropion, sertraline): strong DAT inhibition may lead to false‑negative results.

Moderate Interactions (Monitor Closely): - Antipsychotics (e.g., haloperidol): may modestly affect DAT binding; consider timing of medication relative to scan. - MAO‑B inhibitors (e.g., selegiline): can alter tracer uptake; assess risk‑benefit. - Thyroid hormones: high levels may influence radiotracer kinetics; monitor thyroid status.